HBOT for Late Radiation Tissue Injury: What the Cochrane Review Shows
For radiation proctitis and some head and neck tissue, a Cochrane review found HBOT may help. For other tissues the evidence is thin. An honest look at late radiation injury.
A late complication of cancer treatment
Late radiation tissue injury describes damage that develops months or even years after radiotherapy, as treated tissue slowly loses its blood supply. It can show up as radiation proctitis in the lower bowel, radiation cystitis in the bladder, or osteoradionecrosis, in which irradiated bone, often in the jaw, fails to heal. These complications can be difficult to manage, which is why hyperbaric oxygen therapy has been studied as an option.
The rationale is that HBOT may encourage the growth of new blood vessels in poorly perfused, irradiated tissue, improving the local blood supply so that the tissue can recover or tolerate surgery. Because the damage stems from a lost blood supply rather than active infection, restoring perfusion is the mechanism most often proposed, and it is the basis on which the therapy has been trialled in this group of patients.
What the Cochrane review found
The Cochrane review on hyperbaric oxygen therapy for late radiation tissue injury, first published in 2005 and updated several times, most recently in 2023, pooled the available controlled evidence. Its overall conclusion is cautiously positive for specific sites. The reviewers found some evidence that late radiation injury affecting the head and neck, and the lower end of the bowel, can be improved with HBOT.
In particular, single studies showed a significantly increased chance of improvement or cure for radiation proctitis, and there was evidence supporting the use of HBOT around dental procedures and surgery in irradiated jaw tissue to reduce osteoradionecrosis.
Where the evidence runs out
The same review is clear about its limits. For tissues other than the head, neck, and lower bowel, the reviewers reported little evidence for or against a benefit. That is not a statement that HBOT fails elsewhere, but that the trials needed to answer the question have not been done, or are too small and inconsistent to draw a conclusion.
The evidence base is also modest in size, and the reviewers called for more and better research. Some results in individual settings showed no clear benefit, which is part of an honest picture rather than a footnote.
Like any hyperbaric treatment, HBOT for late radiation injury is not free of side effects, and the reviewers weighed potential harms such as pressure-related ear problems alongside possible benefits. This is another reason the therapy is delivered and monitored in specialist settings rather than treated as routine.
Putting it in context
For patients living with late radiation side effects, this is one of the more encouraging areas of hyperbaric evidence, but the encouragement is site specific. Radiation proctitis and osteoradionecrosis have the strongest support; other tissues remain uncertain.
Because these are hospital-managed protocols delivered in accredited facilities, the question of which manufacturer built a chamber is secondary to whether treatment is clinically indicated, though readers curious about the equipment landscape can review a neutral overview at manufacturer directory. The device is not what determines whether treatment is appropriate.
Late radiation injury is managed within specialist cancer and hyperbaric services. Whether HBOT fits a particular case, and at what point in care, is a decision for the treating oncology and hyperbaric physicians rather than a general rule.